Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed invasive, recurrent, or metastatic
thymoma or thymic carcinoma not amenable to potentially curative therapy Must have
extensive disease defined as: - distant disease - pleural disease with or without
mediastinal involvement - recurrent progressive disease in site of previous radiotherapy
Measurable disease with at least one bidimensionally measurable lesion Must have
octreotide scan prestudy that demonstrates activity in the area of measurable disease
within 6 months prior to registration

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:
Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL
Renal: Creatinine no greater than 3.0 mg/dL Other: No diabetes mellitus or any other
complications to high dose corticosteroid therapy No acute concurrent complications such
as infections Other prior malignancy(ies) must have been curatively treated and
demonstrate no evidence of recurrence Not pregnant or nursing Negative pregnancy test
Adequate contraception required of all fertile patients

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior chemotherapy
allowed if disease progression is demonstrated prior to study entry Endocrine therapy:
Prior or concurrent corticosteroids for myasthenia gravis allowed Radiotherapy: Prior
radiotherapy allowed Surgery: No postsurgical complications